Navigation Links
GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease

MIAMI, Jan. 14, 2011 /PRNewswire/ -- New clinical research data suggests that [18F] Flutemetamol could add value to current diagnostic tools used by physicians and provide accurate identification of beta amyloid plaques, considered to be a sign of neurodegeneration linked to Alzheimer's Disease (AD).  Flutemetamol, a GE Healthcare Positron Emission Tomography (PET) imaging agent currently in phase III development, is being studied to identify the uptake of beta amyloid via imaging of the brain tissue in live humans.  Currently, beta amyloid is identified from brain samples acquired post-mortem. Together with other GE Healthcare imaging modalities, this may help physicians detect amyloid deposition and assist in the detection and treatment of AD.

"The wealth of data presented this year at the annual HAI meeting fundamentally supports the value Flutemetamol could bring to the Alzheimer's community," said Jonathan Allis, MI PET Segment Leader, GE Healthcare Medical Diagnostics.  "The ability to make visual assessments of amyloid in AD patients may enable physicians to seek earlier, confirmed diagnosis of AD and make more informed care decisions."

Data highlights from five clinical abstracts from studies of Flutemetamol to be featured at the 5th Annual Human Amyloid Imaging (HAI) meeting in Miami, Florida suggest that:

  • The in vivo PET retention of Flutemetamol and PIB (Pittsburgh Compound B) have comparable patterns of binding;
  • There is a strong concordance between Flutemetamol amyloid imaging and cortical biopsy histopathology using both visual and quantitative methods;
  • The combination of Flutemetamol and structural MRI can provide information that could be useful in understanding other (non-AD) neuro-degenerative diseases and in identifying beta amyloid formation; and
  • Flutemetamol scans can be categorized with automated software suitable for use in clinical practice.

"At GE Healthcare, our scientists and researchers remain fully committed to developing enhanced diagnostics tools that may help Alzheimer's Disease patients and their families get accurate information as early as possible," said Pascale Witz, CEO, GE Healthcare Medical Diagnostics.

GE Healthcare is taking a comprehensive approach to understanding Alzheimer's Disease through its ongoing research to uncover the causes, risks and physical effects of Alzheimer's Disease. The company's global commitment to advance clinical knowledge and provide a variety of technologies to aid the fight in this epidemic may assist physicians in the acceleration of diagnosis and improvement of treatment decisions in all stages of the disease. GE Healthcare already offers a range of imaging modalities used by physicians to assist in the detection of AD and dementia (CT, MRI, PET, SPECT) and has been a key contributor to the Alzheimer's Disease Neuroimaging Initiative since its inception. The company also plays a key role in PredictAD, an EU-funded research project to develop solutions to enable earlier diagnosis of Alzheimer's disease.  [18F] Flutemetamol is only one part of a broad portfolio of diagnostic solutions that GE Healthcare is currently developing in the Alzheimer's field.


GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our web site at

For our latest news, please visit

For more information, contact:

Aleisia Gibson
Global PR Manager, GE Healthcare, Medical Diagnostics
(609) 514-6046

SOURCE GE Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. ViroPharma to Present at Three Upcoming Healthcare Conferences
4. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
5. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
6. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
7. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
8. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
9. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
10. Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5
11. Immtech to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):